Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review.

导出 LinkOut

翻译打印收藏纠错

作者： Angelika,Buczyńska ^[1] ; Maria,Kościuszko ^[2] ; Adam Jacek,Krętowski ^[3] ; Anna,Popławska-Kita ^[2]

作者单位： Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland. ^[1] Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland. ^[2] Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.;Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland. ^[3]

关键词 DPP-IV Isglt2 adjuvant therapy papillary thyroid cancer thyroid cancer

DOI 10.3389/fphar.2024.1323083

PMID 38292938

发布时间 2024-10-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2024年15卷

1323083页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除